- Home
- DNLI vs ERO Comparison
DNLI vs ERO Comparison
Compare DNLI & ERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DNLI | ERO |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DNLI | ERO |
|---|---|---|
| Price | $24.85 | $26.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 2 |
| Target Price | $34.33 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $51.94 |
| Revenue Next Year | $408.85 | $2.43 |
| P/E Ratio | ★ N/A | $22.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.58 | $12.79 |
| 52 Week High | $25.31 | $39.80 |
Technical Indicators
Market Signals| Indicator | DNLI | ERO |
|---|---|---|
| Relative Strength Index (RSI) | 74.12 | 42.34 |
| Support Level | $18.27 | $24.25 |
| Resistance Level | N/A | $26.77 |
| Average True Range (ATR) | 1.24 | 1.74 |
| MACD | 0.44 | -0.18 |
| Stochastic Oscillator | 88.15 | 15.95 |
Price Performance
Historical ComparisonAbout DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.
About ERO Ero Copper Corp.
Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.